Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Francesco Vittorio Costa"'
Valsartan: come versatilità e tollerabilità possono contribuireal contenimento della spesa sanitaria
Autor:
Francesco Vittorio Costa
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 12, Iss 1S, Pp 9-17 (2011)
The search for a more specific and complete blockade of the hypertensive effects of angiotensin and of better tolerability than ACE-inhibitors has led to the development of angiotensin II receptor blockers (ARBs). ARBs have been evaluated in several
Externí odkaz:
https://doaj.org/article/1129f6697fde4bc1b2946d8d3a6fb3f6
Autor:
Francesco Vittorio Costa
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 10, Iss 4, Pp 161-169 (2009)
This paper summarizes the results of the PAPEETE study (Population-based Analysis of PErsistence with treatment and Economics of TElmisartan) that assessed trends in prescriptions, determinants and timing of treatment discontinuation and/or changes i
Externí odkaz:
https://doaj.org/article/34976886f0af48538ece26b8490f9e92
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 8, Iss 1, Pp 27-45 (2007)
Statins reduce the incidence of cardiovascular events, one of the most important public health problems and among the main leading causes of death. Their use has been increasing in the last decade and today they represent the first drug class in term
Externí odkaz:
https://doaj.org/article/1652d44e128a4ec49dfed4de7132f99b
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 6, Iss 3, Pp 215-226 (2005)
Chronic heart failure (CHF) is the final phase of many common cardiovascular diseases. Consequently, it represents a frequent clinical condition: it’s estimated that in developed countries, Italy included, its prevalence exceeds 3%. CHF is also bur
Externí odkaz:
https://doaj.org/article/d9697b11a8ef45a29878c5b69e2fe301
Autor:
Francesco Vittorio Costa
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 4, Iss 4, Pp 193-200 (2003)
Pharmacoeconomic analysis of antihypertensive treatment should be performed following a correct methodological evaluation and considering with accuracy both costs and benefits of different therapeutic options. Costs evaluation is frequently performed
Externí odkaz:
https://doaj.org/article/f6836ed1e9954f5bb163cee2bf10841f
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 8, Iss 1, Pp 27-45 (2007)
Farmeconomia. Health economics and therapeutic pathways; Vol 8, No 1 (2007); 27-45
Farmeconomia. Health economics and therapeutic pathways; Vol 8, No 1 (2007); 27-45
Statins reduce the incidence of cardiovascular events, one of the most important public health problems and among the main leading causes of death. Their use has been increasing in the last decade and today they represent the first drug class in term
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 6, Iss 3, Pp 215-226 (2005)
Farmeconomia. Health economics and therapeutic pathways; Vol 6, No 3 (2005); 215-226
Farmeconomia. Health economics and therapeutic pathways; Vol 6, No 3 (2005); 215-226
Chronic heart failure (CHF) is the final phase of many common cardiovascular diseases. Consequently, it represents a frequent clinical condition: it’s estimated that in developed countries, Italy included, its prevalence exceeds 3%. CHF is also bur
Autor:
Francesco Vittorio, Costa
Publikováno v:
Journal of hypertension. Supplement : official journal of the International Society of Hypertension. 20(2)
This paper reviews literature data about non-pharmacological treatment of hypertension in women. A reduction in salt intake, an increase in physical activity and body weight reduction have been clearly demonstrated to be effective in reducing blood p